Pharma BD Deal Intelligence

GE HealthCare / SOFIE Biosciences, Inc.

2026 · Acquisition/Merger · $945M · Pending

GE HealthCare agreed to acquire SOFIE Biosciences, a PET radiopharmaceutical contract manufacturer, from private equity firm Trilantic North America for $945 million in cash. SOFIE operates a US network of 15 CMO sites running 21 cyclotrons plus a theranostics-focused CDMO site, and brings US rights to FAPI-74, a Phase III PET radiotracer for pan-cancer imaging. SOFIE will join GE HealthCare's Pharmaceutical Diagnostics (PDx) segment on closing, which the company expects in the first half of 2027. The stated rationale is establishing a final-mile footprint in time-critical PET radiopharmaceutical distribution and participating in radiopharma markets beyond GE HealthCare's own product portfolio. NOTE: ingested at pending_review pending full enrichment.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals